Department of Pediatrics, UNC School of Medicine, Chapel Hill, North Carolina.
UNC Food Allergy Initiative, Chapel Hill, North Carolina.
Clin Exp Allergy. 2019 Apr;49(4):461-470. doi: 10.1111/cea.13305. Epub 2018 Nov 29.
Oral and sublingual immunotherapies for peanut allergy have demonstrated efficacy in small clinical trials; however, mechanisms and biomarkers correlating with clinical outcomes remain elusive. Previous studies have demonstrated a role for IgG in post-OIT plasma in the suppression of IgE-mediated mast cell reactions.
The aim of this study was to characterize the role that peanut oral and sublingual immunotherapy-induced plasma factors play in the inhibition of ex vivo basophil activation and whether inhibitory activity is associated with clinical outcomes.
Plasma samples from subjects on placebo, peanut oral immunotherapy (OIT) or peanut sublingual immunotherapy (SLIT), and IgG-depleted plasma or the IgG fraction were incubated with sensitized basophils, and the inhibition of basophil activation following stimulation with peanut extract was measured. Basophil inhibition results were compared between the two routes of immunotherapy, time on treatment and clinical outcomes.
Plasma from subjects after 12 months of active peanut OIT, but not placebo, inhibits basophil activation ex vivo. Depletion of IgG abrogated the blocking effect of OIT plasma, while the IgG fraction substantially blocked basophil activation. Basophils are inhibited to a similar extent by undiluted OIT and SLIT plasma; however, diluted OIT plasma from the time of desensitization challenge inhibited basophils more than diluted SLIT plasma from time of desensitization challenge. Plasma from subjects who experienced sustained unresponsiveness following OIT inhibited basophils to a greater extent than plasma from subjects who were desensitized, but this was not true for SLIT.
Peanut immunotherapy induces IgG-dependent functional changes in plasma that are associated with OIT but not SLIT clinical outcomes. Understanding the mechanisms of peanut OIT and SLIT may help derive informative biomarkers.
口服和舌下免疫疗法已在小型临床试验中证明对花生过敏有效;然而,与临床结果相关的机制和生物标志物仍然难以捉摸。先前的研究表明,在 OIT 后血浆中的 IgG 在抑制 IgE 介导的肥大细胞反应中起作用。
本研究旨在描述花生口服和舌下免疫治疗诱导的血浆因子在抑制体外嗜碱性粒细胞活化中的作用,以及抑制活性是否与临床结果相关。
在安慰剂、花生口服免疫治疗(OIT)或花生舌下免疫治疗(SLIT)的受试者的血浆样本中,用致敏的嗜碱性粒细胞孵育,测量花生提取物刺激后嗜碱性粒细胞活化的抑制作用。比较两种免疫治疗途径、治疗时间和临床结果之间的嗜碱性粒细胞抑制作用。
在 12 个月的活性花生 OIT 后,而不是安慰剂后,受试者的血浆可抑制体外嗜碱性粒细胞活化。IgG 的耗竭消除了 OIT 血浆的阻断作用,而 IgG 部分则显著阻断了嗜碱性粒细胞的活化。未稀释的 OIT 和 SLIT 血浆对嗜碱性粒细胞的抑制程度相似;然而,从脱敏挑战时间开始,稀释的 OIT 血浆比从脱敏挑战时间开始,稀释的 SLIT 血浆更能抑制嗜碱性粒细胞。OIT 后经历持续无反应的受试者的血浆比脱敏的受试者的血浆更能抑制嗜碱性粒细胞,但 SLIT 则不然。
花生免疫疗法诱导的 IgG 依赖性血浆功能变化与 OIT 相关,但与 SLIT 临床结果无关。了解花生 OIT 和 SLIT 的机制可能有助于得出有意义的生物标志物。